These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27220381)

  • 1. Regional disparities in botulinum toxin A (BoNT-A) therapy for spasticity in Sweden: budgetary consequences of closing the estimated treatment gap.
    Ertzgaard P; Anhammer M; Forsmark A
    Acta Neurol Scand; 2017 Mar; 135(3):366-372. PubMed ID: 27220381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost Efficiency Analysis for Spasticity Management Based on Physician Botulinum Toxin Prescribing Habits.
    Kazerooni R; Howard I; Li X; Verduzco-Gutierrez M
    Arch Phys Med Rehabil; 2022 Jun; 103(6):1205-1209. PubMed ID: 34852255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population.
    Kazerooni R; Watanabe JH
    J Manag Care Spec Pharm; 2021 Apr; 27(4):478-487. PubMed ID: 33511895
    [No Abstract]   [Full Text] [Related]  

  • 4. Inequalities in pharmacologic treatment of spasticity in Sweden - health economic consequences of closing the treatment gap.
    Forsmark A; Rosengren L; Ertzgaard P
    Health Econ Rev; 2020 Feb; 10(1):4. PubMed ID: 32030530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum Toxin Utilization, Treatment Patterns, and Healthcare Costs Among Patients with Spasticity or Cervical Dystonia in the US.
    Hull M; Anupindi VR; DeKoven M; He J; Bouchard J
    Adv Ther; 2023 Sep; 40(9):3986-4003. PubMed ID: 37414904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study.
    Tapias G; García-Romero M; Crespo C; Cuesta M; Forné C; Pascual-Pascual SI
    Farm Hosp; 2016 Sep; 40(5):412-26. PubMed ID: 27570991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cortical activation changes in patients suffering from post-stroke arm spasticity and treated with botulinum toxin a.
    Tomášová Z; Hluštík P; Král M; Otruba P; Herzig R; Krobot A; Kaňovský P
    J Neuroimaging; 2013 Jul; 23(3):337-44. PubMed ID: 22212022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BoNT-A related changes of cortical activity in patients suffering from severe hand paralysis with arm spasticity following ischemic stroke.
    Veverka T; Hluštík P; Tomášová Z; Hok P; Otruba P; Král M; Tüdös Z; Zapletalová J; Herzig R; Krobot A; Kaňovský P
    J Neurol Sci; 2012 Aug; 319(1-2):89-95. PubMed ID: 22687958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity.
    Ward A; Roberts G; Warner J; Gillard S
    J Rehabil Med; 2005 Jul; 37(4):252-7. PubMed ID: 16024483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin A (BoNT-A) for spasticity in adults. What is the evidence?
    Moore AP
    Eur J Neurol; 2002 May; 9 Suppl 1():42-7; dicussion 53-61. PubMed ID: 11918649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining strength training and botulinum neurotoxin intervention in children with cerebral palsy: the impact on muscle morphology and strength.
    Williams SA; Elliott C; Valentine J; Gubbay A; Shipman P; Reid S
    Disabil Rehabil; 2013 Apr; 35(7):596-605. PubMed ID: 22928803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin A for treating spasticity in adults: costly for French hospitals?
    Schnitzler A; Ruet A; Baron S; Buzzi JC; Genet F
    Ann Phys Rehabil Med; 2015 Oct; 58(5):265-8. PubMed ID: 26234276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study.
    Latino P; Castelli L; Prosperini L; Marchetti MR; Pozzilli C; Giovannelli M
    Neurol Sci; 2017 Oct; 38(10):1841-1848. PubMed ID: 28766025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spasticity Treatment Beyond Botulinum Toxins.
    Li S; Winston P; Mas MF
    Phys Med Rehabil Clin N Am; 2024 May; 35(2):399-418. PubMed ID: 38514226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians).
    Bensmail D; Hanschmann A; Wissel J
    J Med Econ; 2014 Sep; 17(9):618-25. PubMed ID: 24841450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvements in healthcare and cost benefits associated with botulinum toxin treatment of spasticity and muscle overactivity.
    Esquenazi A
    Eur J Neurol; 2006 Dec; 13 Suppl 4():27-34. PubMed ID: 17112347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cortical activity modulation by botulinum toxin type A in patients with post-stroke arm spasticity: real and imagined hand movement.
    Veverka T; Hluštík P; Hok P; Otruba P; Tüdös Z; Zapletalová J; Krobot A; Kaňovský P
    J Neurol Sci; 2014 Nov; 346(1-2):276-83. PubMed ID: 25255982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment of spasticity with botulinum toxin type A: an analysis of 1221 treatments in 137 patients.
    Mohammadi B; Balouch SA; Dengler R; Kollewe K
    Neurol Res; 2010 Apr; 32(3):309-13. PubMed ID: 19726016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meaningful improvement in walking performance after Botulinum neurotoxin A (BoNT-A) in chronic spastic patients.
    Cioncoloni D; Taddei S; Bielli S; Annunziata P; Mazzocchio R
    NeuroRehabilitation; 2014; 34(1):185-92. PubMed ID: 24284465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spasticity in practice (SPACE): an international non-interventional study of botulinum neurotoxin type A in treatment-naïve subjects with spasticity.
    Harriss J; Roche N; Cantú-Brito C; Khatkova S; Säterö P; Heitmann S; Simon O; Kliebe-Frisch C; Comes G; Jost WH
    Neurol Neurochir Pol; 2021; 55(2):165-173. PubMed ID: 33433902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.